Myopathy News and Research

RSS

The myopathies are neuromuscular disorders in which the primary symptom is muscle weakness due to dysfunction of muscle fiber. Other symptoms of myopathy can include include muscle cramps, stiffness, and spasm. Myopathies can be inherited (such as the muscular dystrophies) or acquired (such as common muscle cramps).

Massive microRNA scan uncovers leads to treating muscle degeneration

Researchers have discovered the first microRNAs - tiny bits of code that regulate gene activity - linked to each of 10 major degenerative muscular disorders, opening doors to new treatments and a better biological understanding of these debilitating, poorly understood, often untreatable diseases.

18 Oct 2007

New strategy for treating rare muscle disease, kidney disorders

Based on clues provided by a study with transgenic mice, a research group at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), has developed a strategy that will be tested as the first treatment for people with hereditary inclusion body myopathy (HIBM), a rare, degenerative muscle disease.

3 Jun 2007

Rosuvastatin well tolerated by a broad range of patients with dyslipidemia

The safety and tolerability of rosuvastatin were assessed using data from 16,876 patients who received rosuvastatin 5-40 mg in a multinational phase II/III/IIIb/IV program, representing 25,670 patient-years of continuous exposure to rosuvastatin. An integrated database, consisting of 33 trials whose databases were locked up to and including September 16, 2005, was used to examine adverse events and laboratory data.

9 May 2007

Schering-Plough announces ZETIA spproved in Japan

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ZETIA (ezetimibe), a novel cholesterol-lowering agent that inhibits the absorption of cholesterol in the intestine.

20 Apr 2007

Research illustrates BAG3 protein's importance in maintaining mature skeletal muscle

Muscle cells that should grow stronger with use instead self-destruct when a protein called BAG3 isn't around, researchers have shown.

30 Aug 2006

Discovery of gene that may play a role in centronuclear myopathy

By studying the molecules that regulate the formation of muscle, researchers at UT Southwestern Medical Center have discovered a gene that may play a role in a rare muscular disease in humans.

31 Aug 2005

Most serious side effects in statins may be higher in one of the newest drugs, rosuvastatin (Crestor)

A post-market analysis of cholesterol-lowering drugs called statins indicates that some of the most serious side effects may be higher in one of the newest drugs, rosuvastatin (Crestor). The drug is the strongest statin available because it has the greatest effect per milligram on low-density lipoprotein ("bad" cholesterol).

26 May 2005

Women more vulnerable to chronic drinking than men are

A study in the May issue of Alcoholism: Clinical & Experimental Research addresses this gap in research, using computed tomography (CT) to examine brain atrophy in the brains of alcoholic men and women. The findings support and build upon a prior hypothesis that women develop alcohol-related brain damage more readily than men.

16 May 2005

Fourth gene found for distal muscular dystrophy

MDA grantees Peter Hedera, a neurologist at Vanderbilt University in Nashville, Tenn., and Nigel Laing, a molecular biologist at the University of Western Australia, were part of a team that identified a fourth gene that, when flawed, leads to distal muscular dystrophy (DD).

4 Oct 2004

Early use of aggressive statin therapy may offer some benefit for coronary patients

Statins initiated early after a patient experiences an acute coronary syndrome (ACS) event at dosages above the typical starting dose may help reduce subsequent cardiovascular events, but the high dose regimen used may increase the risk for muscle-related complications, according to the results from the Phase Z portion of the A to Z Trial released on the JAMA website today.

30 Aug 2004

First Approval in Europe of Ezetimibe/Simvastatin for treatment of elevated cholesterol

Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad’ cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU’s mutual recognition procedure.

4 Apr 2004